CASI Pharmaceuticals, Inc. SEC filings CASIF
CASI Pharmaceuticals, Inc. has 157 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 18, 2026 | — |
| 3 | Initial insider ownership | Apr 23, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 20, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 13, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 7, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 3, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Apr 3, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 27, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 25, 2026 | Mar 18, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 23, 2026 | — |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 10, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 29, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 20, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 20, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 9, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 18, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 17, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 26, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Sep 26, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 12, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 23, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 20, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 3, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 29, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Aug 12, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Jul 25, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Jun 20, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jun 11, 2024 | — |
| 144 | Notice of proposed sale | Mar 15, 2024 | — |
| 144 | Notice of proposed sale | Mar 5, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 26, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 9, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jun 23, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Apr 18, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Apr 10, 2023 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CASIF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Beijing, China
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1962738
- Former names
- CASI Pharmaceuticals Holdings, Inc. (until Feb 14, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.